Recent research into the pathophysiology of these intensely itchy PN lesions shows that interleukin 31 (IL-31), an inflammatory cytokine, directly stimulates sensory nerves through upregulation of IL-31 receptor alpha (IL-31-RA), generating the intense sensation of itch experienced by patients with PN.4 Skin biopsies of PN patients show a thickening of dermal nerve fibers with a decreased density in intraepidermal nerve fibers and increased expression of neuropeptides, which leads to the activation of cytokine receptors, like IL-31-RA, on the sensory nerves that cause inflammation and the intense itch experienced by patients with PN.3-5 In fact, studies of PN lesions show a 50-fold increase of IL-31 in mRNA expression compared with healthy skin.2
Although PN can occur without any underlying disease, many patients with PN have associated dermatologic, systemic, neurologic, and psychological diseases of mixed origin that present along with PN.6 Systemic diseases commonly associated with PN include atopic dermatitis, attention deficit/hyperactivity disorder, cerebrovascular disease, chronic kidney disease, chronic obstructive pulmonary disease, types 1 and 2 diabetes, heart failure, HIV, hypertension, and cancer.1,7 Regardless of the underlying cause, PN is a distinct dermatologic disease that can be diagnosed by a dermatologist or other qualified physician and requires management of symptoms, since the pathophysiology of the disease is more difficult to address.2,3
References:
1.Huang AH, Williams KA, Kwatra SG. Prurigo nodularis: epidemiology and clinical features. J Am Acad Dermatol. 2020;83(6):1559-1565. doi:10.1016/j.jaad.2020.04.183
2.Kowalski EH, Kneiber D, Valdebran M, Patel U, Amber KT. Treatment-resistant prurigo nodularis: challenges and solutions. Clin Cosmet Investig Dermatol. 2019;12:163-172. doi:10.2147/CCID.S188070
3.Ständer S, Pereira MP, Berger T, et al. IFSI-guideline on chronic prurigo including prurigo nodularis. Itch. 2020;5(4):e42. doi:10.1097/itx.0000000000000042
4.Datsi A, Steinhoff M, Ahmad F, Alam M, Buddenkotte J. Interleukin-31: the “itchy” cytokine in inflammation and therapy. Allergy. 2021;76(10):2982-2997. doi:10.1111/all.14791
5.Williams KA, Huang AH, Belzberg M, Kwatra SG. Prurigo nodularis: pathogenesis and management. J Am Acad Dermatol. 2020;83(6):1567-1575. doi:10.1016/j.jaad.2020.04.182 (P.3, C.2, Ph.2, L.1-17) (P.2, C.2, Ph.3, L.6-8)
6.Iking A, Grundmann S, Chatzigeorgakidis E, Phan NQ, Klein D, Ständer S. Prurigo as a symptom of atopic and non-atopic diseases: aetiological survey in a consecutive cohort of 108 patients. J Eur Acad Dermatol Venereol. 2013;27(5):550-557. doi:10.1111/j.1468-3083.2012.04481.x
7.Huang AH, Canner JK, Khanna R, Kang S, Kwatra SG. Real-world prevalence of prurigo nodularis and burden of associated diseases. J Invest Dermatol. 2020;140(2):480-483.e4. doi:10.1016/j.jid.2019.07.697